Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (91-100 of 437) with videos related to

Pageof 44
Sort By:
Deutsches Arzteblatt International|May 18, 2023
Lung Cancer Screening With Low-Dose Computed TomographyMartin Reck, Sabine Dettmer, Hans-Ulrich Kauczor, et al.
Oncology Reports|May 23, 2012
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancerOfer Merimsky, Chi-Kin Cheng, Joseph Siu-Kie Au, et al.
Drugs|September 28, 2020
First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future DirectionsChristoph Jakob Ackermann, Helen Adderley, Ana Ortega-Franco, et al.
Lung Cancer (Amsterdam, Netherlands)|August 11, 2012
An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastasesAlan Sandler, Vera Hirsh, Martin Reck, et al.
Clinical Lung Cancer|October 4, 2015
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based ChemotherapyJonathan W Goldman, Peipei Shi, Martin Reck, et al.
Onkologie|June 5, 2010
[Current developments and perspectives in targeted therapies]Nicolas Dickgreber, Rudolf M Huber, Martin Reck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2010
Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL)Natasha B Leighl, Petr Zatloukal, Jörg Mezger, et al.
Journal of Pain and Symptom Management|December 15, 2015
Dimensionality, Stability, and Validity of the Beck Hopelessness Scale in Cancer Patients Receiving Curative and Palliative TreatmentLena Spangenberg, Markus Zenger, Francisco Garcia-Torres, et al.
Frontiers in Oncology|September 21, 2023
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature reviewEdward B Garon, Carla Visseren-Grul, Maria Teresa Rizzo, et al.
Onkologie|September 16, 2006
[Therapy for non-small-cell lung carcinoma (NSCLC) in stage IV]Karl-Matthias Deppermann, Rudolf M Huber, Eckart Laack, et al.
Pageof 44

Showing results (91-100 of 437) with videos related to

Sort By:
Pageof 44
Deutsches Arzteblatt International|May 18, 2023
Lung Cancer Screening With Low-Dose Computed TomographyMartin Reck, Sabine Dettmer, Hans-Ulrich Kauczor, et al.
Oncology Reports|May 23, 2012
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancerOfer Merimsky, Chi-Kin Cheng, Joseph Siu-Kie Au, et al.
Drugs|September 28, 2020
First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future DirectionsChristoph Jakob Ackermann, Helen Adderley, Ana Ortega-Franco, et al.
Lung Cancer (Amsterdam, Netherlands)|August 11, 2012
An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastasesAlan Sandler, Vera Hirsh, Martin Reck, et al.
Clinical Lung Cancer|October 4, 2015
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based ChemotherapyJonathan W Goldman, Peipei Shi, Martin Reck, et al.
Onkologie|June 5, 2010
[Current developments and perspectives in targeted therapies]Nicolas Dickgreber, Rudolf M Huber, Martin Reck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2010
Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL)Natasha B Leighl, Petr Zatloukal, Jörg Mezger, et al.
Journal of Pain and Symptom Management|December 15, 2015
Dimensionality, Stability, and Validity of the Beck Hopelessness Scale in Cancer Patients Receiving Curative and Palliative TreatmentLena Spangenberg, Markus Zenger, Francisco Garcia-Torres, et al.
Frontiers in Oncology|September 21, 2023
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature reviewEdward B Garon, Carla Visseren-Grul, Maria Teresa Rizzo, et al.
Onkologie|September 16, 2006
[Therapy for non-small-cell lung carcinoma (NSCLC) in stage IV]Karl-Matthias Deppermann, Rudolf M Huber, Eckart Laack, et al.
Pageof 44